Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and...

Area of Science:

• Oncology
• Pathology
• Molecular Diagnostics

Background:

• Targeted therapies have transformed advanced non-small cell lung cancer (NSCLC) treatment.
• Accurate histological diagnosis and predictive biomarker identification are critical for treatment selection.
• Managing biopsies for multiple simultaneous assays presents a significant challenge.

Purpose of the Study:

• To highlight the importance of balancing precise histological diagnosis with simultaneous predictive biomarker assays in NSCLC.
• To propose a protocol for prioritizing samples in the era of targeted therapy.
• To integrate recent technological advances and molecular classification discoveries into NSCLC management.

Main Methods:

• Review of current practices in NSCLC biopsy handling and analysis.
• Emphasis on multidisciplinary tumor board collaboration.
• Integration of molecular classification and technological advancements into a proposed protocol.

Main Results:

• Precise histological diagnosis is paramount for effective targeted therapy selection.
• Simultaneous predictive assays require careful sample prioritization and management.
• Multidisciplinary collaboration ensures a rational and effective protocol.

Conclusions:

• A balanced approach integrating histology, biomarker testing, and multidisciplinary input is essential for optimal NSCLC patient care.
• Proposed protocols incorporating advanced diagnostics and molecular insights can improve treatment outcomes.
• Effective management of NSCLC relies on a coordinated effort from tumor boards and diagnostic laboratories.